FINWIRES · TerminalLIVE
FINWIRES

道明银行表示,推动加拿大零售销售增长的可能是物价上涨而非全面需求增长。

-- TD经济分析师玛丽亚·索洛维耶夫(Maria Soloviev)在周五公布2月份零售销售数据后表示,消费者在2月份再次展现了“稳健”的消费表现,初步迹象表明3月份的消费势头将延续。但3月份通胀率飙升,表明部分增长动力并非源于全面需求增长,而是由物价上涨推动。 她在分析周五公布的数据时指出,TD内部支出数据显示,3月份可自由支配支出有所放缓。 索洛维耶夫表示,能源价格上涨将削弱购买力,但TD预计这不会对国内需求造成实质性削弱,其影响已包含在TD的预期之中。她补充说,加上人口增长疲软和贸易相关不利因素的拖累,预计今年经济增长速度将低于趋势水平。 TD指出,2月份零售销售额环比增长0.7%,连续第二个月保持增长势头。这一数字低于加拿大统计局此前预估的0.9%的增幅。从数量上看,活动环比仅增长0.3%,增幅较为温和,表明整体增长主要受价格上涨推动。 展望未来,加拿大统计局的初步估计显示,3月份活动环比将进一步增长0.6%。

Related Articles

Asia

National Australia Bank Shares Down After Resolution of Union Court Proceedings

National Australia Bank (ASX:NAB) shares were down about 1% in recent Monday trade following a Friday settlement with the Finance Sector Union of Australia to resolve court proceedings related to excessive additional working hours for employees.The settlement, reached on a without-admissions basis through mediation, includes the establishment of a health, safety, and well-being framework to mitigate the risks linked to working additional hours, and calls for greater oversight of such risks.The union and the bank said in a joint statement that they are "committed to continuing to work together to ensure fair and sustainable outcomes for all [National Australia Bank] employees."

$ASX:NAB
Asia

Clinuvel Pharmaceuticals Says FDA Removes Post-Authorization Requirement for Implant

Clinuvel Pharmaceuticals (ASX:CUV) said the US Food and Drug Administration (FDA) removed a requirement for a post-authorization phase one study on cardiac repolarization in relation to its Scenesse implant upon reviewing its long-term safety profile, according to a Monday filing with the Australian bourse.Scenesse is used to treat patients with erythropoietic protoporphyria, a disease that causes intolerance to light.The FDA concluded that the study was no longer needed since it would not yield valuable safety information, the filing said.

$ASX:CUV
Asia

XRF Scientific Completes Acquisition of Combustion Gas Analysis Business

XRF Scientific (ASX:XRF) has completed the acquisition of the combustion gas analysis business from Bruker AXS, according to a Monday Australian bourse filing.The company entered a binding agreement to acquire the combustion gas analysis business for $4 million upfront plus a potential $1 million earnout based on 7% of net revenue over three years, an earlier filing showed.

$ASX:XRF